Canaccord analyst William Plovanic lowered the firm’s price target on Acutus Medical to $1.00 from $1.91 and keeps a Hold rating on the shares. The analyst said we believe the company will leverage its existing US customer base and leaner organization to drive increasing growth and decreasing operating losses and cash usage.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on AFIB:
- Acutus Medical sees FY23 revenue $18M-$21M, consensus $20.46M
- Acutus Medical reports Q4 EPS (63c), consensus (71c)
- Acutus Medical Reports Fourth Quarter and Full Year 2022 Financial Results
- Acutus Medical management to meet virtually with BTIG
- Acutus Medical to Announce Fourth Quarter and Full Year 2022 Financial Results